Top

Radiation Oncology

Published in:

Open Access 01-12-2022 | Breast Cancer | Research

Effect of postoperative radiotherapy in women with localized pure mucinous breast cancer after lumpectomy: a population-based study

Authors: Qiuping Mo, Yongzhen Wang, JinLan Shan, Xiaochen Wang

Published in: Radiation Oncology | Issue 1/2022

Abstract

Purpose

Pure mucinous breast cancer is a rare subtype of invasive breast cancer with favorable prognosis, in which the effect of postoperative radiotherapy remains unclear. We aimed to investigate the prognostic value of postoperative radiotherapy in women with localized pure mucinous breast cancer after lumpectomy.

Methods

We conducted a retrospective cohort study to compare the effectiveness of postoperative radiotherapy (RT) and omitting postoperative radiotherapy (non-RT) in patients with first primary T1-2N0M0 (T ≤ 3 cm) pure mucinous breast cancer who underwent lumpectomy between 1998 and 2015 using the Surveillance, Epidemiology, and End Results (SEER) database. Breast cancer-specific survival (BCSS) was compared between RT and non-RT groups using Kaplan–Meier method and Cox proportional hazards regression model. Propensity score matching (PSM) was carried out to balance cohort baselines. In addition, an exploratory analysis was performed to verify the effectiveness of RT in subgroup patients.

Results

Of 7832 eligible patients, 5352 (68.3%) underwent lumpectomy with postoperative RT, 2480 (31.7%) received lumpectomy without postoperative RT. The median follow-up duration was 92 months. The median age was 66 years in the RT group and 76 years in the non-RT group.The 15-year BCSS was 94.39% (95% CI, 93.08% to 95.35%) in the RT group versus 91.45%(95% CI, 88.93% to 93.42%) in the non-RT group (P < 0.001). The adjusted hazard ratio for BCSS was 0.64 (95% CI, 0.49 to 0.83; P = 0.001) for RT group versus non-RT group. After propensity score matching, similar results were yielded. Adjuvant RT reduced the 15-year risk of breast cancer death from 7.92% to 6.15% (P = 0.039). The adjusted hazard ratio for BCSS were 0.66 (95%CI, 0.47 to 0.92; P = 0.014) for RT group versus non-RT group. The benefit of RT was well consistent across subgroup patients.

Conclusion

Among women with T1-2N0M0 (tumor size ≤ 3 cm) pure mucinous breast cancer, the addition of RT after lumpectomy was significantly associated with a reduced incidence of breast cancer death compared with non-RT, and the magnitude of benefit may be modest. This suggests that postoperative RT is recommended in the treatment of localized pure mucinous breast cancer.

Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 1999;17(5):1442–8. https://doi.org/10.1200/jco.1999.17.5.1442.CrossRefPubMed

The world Health Organization Histological Typing of Breast Tumors--Second Edition. The World Organization. Am J Clin Pathol. 1982;78(6):806–16. https://doi.org/10.1093/ajcp/78.6.806.

Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat. 2008;111(3):541–7. https://doi.org/10.1007/s10549-007-9809-z.CrossRefPubMed

Lei L, Yu X, Chen B, Chen Z, Wang X. Clinicopathological characteristics of mucinous breast cancer: a retrospective analysis of a 10-year study. PLoS ONE. 2016. https://doi.org/10.1371/journal.pone.0155132.CrossRefPubMedPubMedCentral

Lacroix-Triki M, Suarez PH, MacKay A, Lambros MB, Natrajan R, Savage K, et al. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. The J pathol. 2010;222(3):282–98. https://doi.org/10.1002/path.2763.CrossRefPubMed

Bae SY, Choi MY, Cho DH, Lee JE, Nam SJ, Yang JH. Mucinous carcinoma of the breast in comparison with invasive ductal carcinoma: clinicopathologic characteristics and prognosis. J Breast Cancer. 2011;14(4):308–13. https://doi.org/10.4048/jbc.2011.14.4.308.CrossRefPubMedPubMedCentral

Thurman SA, Schnitt SJ, Connolly JL, Gelman R, Silver B, Harris JR, et al. Outcome after breast-conserving therapy for patients with stage I or II mucinous, medullary, or tubular breast carcinoma. Int J Radiat Oncol, Biol, Phys. 2004;59(1):152–9. https://doi.org/10.1016/j.ijrobp.2003.10.029.CrossRef

Anderson WF, Pfeiffer RM, Dores GM, Sherman ME. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol, Biomark & Prevent : A Publ Am Assocr Cancer Res, Cospons Am Soc Prevent Oncol. 2006;15(10):1899–905. https://doi.org/10.1158/1055-9965.epi-06-0191.CrossRef

Skotnicki P, Sas-Korczynska B, Strzepek L, Jakubowicz J, Blecharz P, Reinfuss M, et al. Pure and mixed mucinous carcinoma of t: a comparison of clinical outcomes and treatment resultshe breast. Breast J. 2016;22(5):529–34. https://doi.org/10.1111/tbj.12621.PubMedPMID:WOS:000383520200006.CrossRefPubMed

10.

Wasif N, McCullough AE, Gray RJ, Pockaj BA. Influence of uncommon histology on breast conservation therapy for breast cancer-biology dictates technique? J Surg Oncol. 2012;105(6):586–90. https://doi.org/10.1002/jso.22132.PubMedPMID:WOS:000302550200012.CrossRefPubMed

11.

Cao AY, He M, Liu ZB, Di GH, Wu J, Lu JS, et al. Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma: a population-based study from China. Ann Surg Oncol. 2012;19(9):3019–27. https://doi.org/10.1245/s10434-012-2322-6.CrossRefPubMed

12.

Louwman MW, Vriezen M, van Beek MW, Nolthenius-Puylaert MC, van der Sangen MJ, Roumen RM, et al. Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer. 2007;121(1):127–35. https://doi.org/10.1002/ijc.22625.CrossRefPubMed

13.

Fu J, Wu L, Jiang M, Li D, Jiang T, Hong Z, et al. Clinical nomogram for predicting survival outcomes in early mucinous breast cancer. PLoS ONE. 2016. https://doi.org/10.1371/journal.pone.0164921.CrossRefPubMedPubMedCentral

14.

Ishikawa T, Hamaguchi Y, Ichikawa Y, Shimura M, Kawano N, Nakatani Y, et al. Locally advanced mucinous carcinoma of the breast with sudden growth acceleration: a case report. Jp J Clin Oncol. 2002;32(2):64–7. https://doi.org/10.1093/jjco/hyf012.CrossRef

15.

Fujii H, Anbazhagan R, Bornman DM, Garrett ES, Perlman E, Gabrielson E. Mucinous cancers have fewer genomic alterations than more common classes of breast cancer. Breast Cancer Res Treat. 2002;76(3):255–60. https://doi.org/10.1023/a:1020808020873.PubMedPMID:WOS:000178929800008.CrossRefPubMed

16.

Pareja F, Lee JY, Brown DN, Piscuoglio S, Gularte-Merida R, Selenica P, et al. The genomic landscape of mucinous breast cancer. J Natl Cancer Inst. 2019. https://doi.org/10.1093/jnci/djy216.PubMedPMID:MEDLINE:30649385.CrossRefPubMedPubMedCentral

17.

Rasmussen BB, Rose C, Christensen IB. Prognostic factors in primary mucinous breast carcinoma. Am J Clin Pathol. 1987;87(2):155–60. https://doi.org/10.1093/ajcp/87.2.155.CrossRefPubMed

18.

Avisar E, Khan MA, Axelrod D, Oza K. Pure mucinous carcinoma of the breast: a clinicopathologic correlation study. Ann Surg Oncol. 1998;5(5):447–51 (Epub 1998/08/26 PubMed PMID: 9718175).CrossRef

19.

Gwark SC, Lee HS, Lee Y, Lee SB, Sohn G, Kim J, et al. Clinical implication of HER2 status in hormone receptor-positive mucinous breast cancer. Ann Surg Oncol. 2019;26(7):2166–74. https://doi.org/10.1245/s10434-019-07332-9.CrossRefPubMed

20.

Ding S, Wu J, Lin C, Chen W, Li Y, Shen K, et al. Predictors for survival and distribution of 21-gene recurrence score in patients with puremucinous breast cancer: a SEER population-based retrospective analysis. Clin Breast Cancer. 2018. https://doi.org/10.1016/j.clbc.2018.10.001.PubMedPMID:MEDLINE:30396812.CrossRefPubMed

21.

NCCN Clinical Practice Guidelines in Breast Cancer (Version 3.2022). Available from: http://www.nccn.org.

22.

Ding S, Wu J, Lin C, Chen W, Li Y, Shen K, et al. Predictors for survival and distribution of 21-gene recurrence score in patients with pure mucinous breast cancer: a SEER population-based retrospective analysis. Clin Breast Cancer. 2019;19(1):e66-73. https://doi.org/10.1016/j.clbc.2018.10.001.CrossRefPubMed

23.

Wu SG, Li FY, Wang J, Lian CL, Zhou J, He ZY. Omission of adjuvant radiotherapy following breast-conserving surgery for elderly women with early-stage pure mucinous breast carcinoma. Radiat Oncol (London, England). 2019;14(1):190. https://doi.org/10.1186/s13014-019-1394-x.CrossRef

24.

National Cancer Institute: surveillance, epidemiology, and end results. Available from: https://seer.cancer.gov/.

25.

Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012;30(7):729–34. https://doi.org/10.1200/jco.2011.36.2574.CrossRefPubMed

26.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95. https://doi.org/10.1200/jco.2009.25.6529.CrossRefPubMedPubMedCentral

27.

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (London, England). 2005;366(9503):2087–106. https://doi.org/10.1016/s0140-6736(05)67887-7.CrossRef

28.

Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet (London, England). 2011;378(9804):1707–16. https://doi.org/10.1016/s0140-6736(11)61629-2.CrossRef

29.

Liljegren G, Holmberg L, Bergh J, Lindgren A, Tabar L, Nordgren H, et al. 10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol. 1999;17(8):2326–33. https://doi.org/10.1200/jco.1999.17.8.2326.CrossRefPubMed

30.

Pan B, Yao R, Shi J, Xu Q-Q, Zhou Y-D, Mao F, et al. Prognosis of subtypes of the mucinous breast carcinoma in Chinese women: a population-based study of 32-year experience (1983–2014). Oncotarget. 2016;7(25):38864–75. https://doi.org/10.18632/oncotarget.8778.PubMedPMID:WOS:000378229100116.CrossRefPubMedPubMedCentral

31.

Vo T, Xing Y, Meric-Bernstam F, Mirza N, Vlastos G, Symmans WF, et al. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg. 2007;194(4):527–31. https://doi.org/10.1016/j.amjsurg.2007.06.012.CrossRefPubMed

32.

Wang W, Chen X, Lin L, Fei X, Garfield DH, Hong J, et al. Distribution and clinical utility of the 21-gene recurrence score in pure mucinous breast cancer patients: a case-control study. J Cancer. 2018;9(18):3216–24. https://doi.org/10.7150/jca.27291.PubMedPMID:WOS:000444015800001.CrossRefPubMedPubMedCentral

Title: Effect of postoperative radiotherapy in women with localized pure mucinous breast cancer after lumpectomy: a population-based study
Authors: Qiuping Mo
Yongzhen Wang
JinLan Shan
Xiaochen Wang
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Radiotherapy
Published in: Radiation Oncology / Issue 1/2022
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/s13014-022-02082-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effect of postoperative radiotherapy in women with localized pure mucinous breast cancer after lumpectomy: a population-based study

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

Assessment of IMPT versus VMAT plans using different uncertainty scenarios for prostate cancer

A prospective comparison of adaptive and fixed boost plans in radiotherapy for glioblastoma

The role of neoadjuvant radiochemotherapy in the management of localized high-grade soft tissue sarcoma

Treatment results for patients with squamous-cell carcinoma of the anus, a single institution retrospective analysis

Ways to unravel the clinical potential of carbon ions for head and neck cancer reirradiation: dosimetric comparison and local failure pattern analysis as part of the prospective randomized CARE trial

Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study